asp3652

ASP3652 is a peripherally acting, orally administered small molecule inhibitor of fatty acid amide hydrolase (FAAH). FAAH is an enzyme responsible for the degradation of endocannabinoids such as anandamide. By inhibiting FAAH, ASP3652 increases levels of endocannabinoids, which are thought to modulate pain signaling. The drug was originally developed by Astellas Pharma and has been investigated primarily for the treatment of chronic pelvic pain disorders, including chronic pelvic pain syndrome, chronic prostatitis, and bladder pain syndrome/interstitial cystitis. Clinical trials have evaluated its safety, tolerability, pharmacokinetics, and efficacy in these indications. In 2021, Autobahn Therapeutics acquired global rights to ASP3652 from Astellas Pharma.